The global fertility drugs market is anticipated to grow at a considerable CAGR of around 5.1% during the forecast period.  Infertility is one of the major issues now a day due to change in life style & cultural shift. There are various fertility drugs available in market for infertility related problems. Fertility drugs enhance the reproductive ability by improving quality of egg or sperms by increasing the levels of certain hormones in human body. The major factors that are responsible for the growth of fertility drug market are change in lifestyle and cultural shift, increasing prevalence of obesity, increasing infertility rate in adults, rising average age of conceiving in woman and rise in sexually transmitted diseases among men and women. However, high cost of fertility drugs & risk associated with the use of fertility drugs such as ovarian hyper stimulation syndrome (OHS) are the major constraints to the market. Whereas increasing awareness about the fertility drugs among the people is creating immense opportunities for future. 

The fertility rate has declined over the past few years. According to the Vital Statistics Rapid Release report, the provisional number of births for the United States in 2020 was 3,605,201, down 4% from 2019. Moreover, in 2020, birth rates declined for women in all age groups 15–44 and were unchanged for adolescents aged 10–14 and women aged 45–49. The birth rate for teenagers aged 15–19 declined by 8% in 2020 to 15.3 births per 1,000 females; rates declined for both younger (aged 15–17) and older (aged 18–19) teenagers. Declined in the fertility rate for various reasons leads to higher consumption of fertility drugs, which in turn contributes to the growth of the global fertility drug market. 

Impact of COVID-19 Pandemic on Global Fertility Drugs Market 

The COVID-19 pandemic has devastated lives across the world, with 4.6 million deaths and counting. Health systems across the world have been overwhelmed by the COVID-19 pandemic, meanwhile the countries failing to keep sexual and reproductive health services available, resulting in neglect and an increase in risks to women’s health. The United Nations Population Fund has identified that in 115 low- and middle-income countries an average of 3.6 months of disruption was faced by women who couldn’t access family planning services, resulting in a projected 7 million unintended pregnancies. In Nepal, the pandemic weakened maternal health services, with an increase in maternal deaths as 258 women died as a result of pregnancy or childbirth between March 2020 and June 2021, compared with 51 maternal deaths in the year before COVID-19. 

 Segmental Outlook 

The global fertility drug market is segmented on the basis on gender type, treatment type and infertility type. Based on gender type, the market is segmented into female fertility treatment, male fertility treatment. Based on treatment type, the market is sub-segmented into hormonal, in vitro fertilization (ivf), intra cytoplasmic sperm injection (icsi), intrauterine insemination (iui), and alternative and complementary treatment. Based on infertility type, the market is sub-segmented into problem with ovulating, unexplained infertility, blocked or damaged tubes, endometriosis, polycystic ovarian syndrome

Global Fertility Drugs Market Share by Treatment Type, 2021 (%)

In Vitro Fertilization (IVF) segment is augmented to grow at the Fastest Rate in Global Fertility Drugs Market

In-vitro fertilization (IVF) is one of the widely used treatments, which assisted couples with infertility problems, single mothers, and the LGBT community to procreate. An increase in infertility rate, a rise in the trend of delayed pregnancies, a surge in IVF success rate, and technological advancements in IVF treatment, are the major driving factor that contributes to the growth of the segment. The contribution of key market players in the market fueled the growth of the IVF segment during the forecast period. for instance,  in January 2021, Royal Philips announced a multi-year partnership with Merck, to develop clinical-grade digital solutions for highly personalized fertility treatment. Leveraging digital health technologies, advanced informatics, and AI-enabled ultrasound diagnostics, this solution aimed to better inform the patients about the choice and timing of fertility treatment. 

Regional Outlooks

The global fertility drugs market is further segmented based on geography including North America (the US, and Canada Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  Asia-Pacific is expected to be the fastest-growing region mainly due to the rising government initiatives to establish fertility clinics, and initiatives taken by large international healthcare providers to establish fertility centers, are some of the major factors likely to contribute to the rapid growth of the market in the region.  

Global Fertility Drugs Market Growth, by Region 2021-2028

North America Region Dominated the Global Fertility Drugs Market 

North America is holding the largest market share of the global fertility drug market. The North American region presents productive opportunities for key market players operating in the fertility drug market, owing to its high population base, growth in knowledge regarding fertility drugs, and rise in popularity of IVF in the region, are the basic factor that enhances the market growth in the North America region. Moreover, the insurance coverage provided by the insurance companies which includes coverage for infertility diagnosis, and treatment in their policies, contribute to the growth of the market. For instance, according to the Reproductiverights.org, in 2019, 17 states in the US have insurance laws, also known as state mandates, which require the insurance companies to include coverage for fertility diagnosis, and treatment in their policies. Of these, 11 specifically require coverage for IVF.  

Market Players Outlook

The major companies serving the global fertility drugs market F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals Inc., Johnson & Johnson Pvt. Ltd., Leadiant Biosciences Inc., and Merck & Co. Pharmaceutical Co., Noven Pharmaceutical organon, Inc., Pfizer Inc.,  and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2020, Cyroport Inc., agreed with the Colorado Center for Reproductive Medicine (CCRM). Under the terms of the agreement cryoport’s temperature control support CCRM’s fertility treatment, including in-vitro fertilization (IVF), fertility preservation third-party reproduction, and egg donation.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global fertility drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. 
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.